| |
|
|
| |
| |
| EAU Newsletter December 2016 |
| |
|
| |
It´s the season to be merry and hopeful for the coming new year. So far, 2016 has been an eventful and memorable one. What better way to bring this year to a close but with more things to look forward to in 2017?
Grab a sneak peek of EAU17, the must-attend event to refine your knowledge and skills. Read on about a new e-course on mPCa and look back on the highlights of our multidisciplinary EMUC16 meeting. These and more await you in this month’s newsletter.
Wishing you a joyful holiday season and a happy new year! |
|
|
|
| |
 |
| |
Take advantage of the early fee and register now for the upcoming 32nd Annual EAU Congress in London! The early bird deadline is 16 January 2017. Please note that only online registrations will be accepted.
|
|
| |
|
Last month, the EAU received several awards in recognition of its contributions to urology worldwide. The Association Francaise d’Urologie (AFU) awarded the Félix Guyon Medal to the EAU which is intended to honour services rendered to both urology and the AFU. For EAU’s support, cooperation and contribution to urology in China, the Chinese Urological Association (CUA) awarded the EAU with the CUA Best Strategic Partner Award.
|
|
|
|
| |
The much-awaited 4th Meeting of the EAU Section of Urolithiasis (EULIS17) will take place from 5 to 7 October 2017 in Vienna, Austria. This meeting will focus on the numerous scientific developments and clinical applications in the pathophysiology, diagnosis, metabolic evaluation, medical and surgical treatment of stone disease. Mark your calendars and pre-register now for EULIS17! |
|
|
|
| |
A growing number of papers, consensus meetings, and clinical trials are addressing the role of focal therapy (FT) in the treatment of prostate cancer (PCa). Will FT become a standard option in selected men with localised PCa? To investigate the current opinion on the role of FT for PCa amongst European urologists, the Young Academic Urologists (YAU) have developed a FT survey. The online survey consists of 23 questions addressing demographics of physicians, focal therapy, and clinical cases. |
|
|
|
| |
 The new e-course on metastatic prostate cancer (mPCa)offers an overview on the state-of-the-art of the clinical diagnosis and treatment of mPCa. This course is divided in 2 modules that show an in-depth approach to both cases castrate-sensitive and castrate-resistant prostate cancer and treatments. Get ready to test your knowldge in the treatment of mPCa patients and earn accreditation at the same time! |
|
|
|
|
|
